Eintrag weiter verarbeiten
Effects of glucosamine infusion on insulin secretion and insulin action in humans.
Gespeichert in:
| Zeitschriftentitel: | Diabetes |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , |
| In: | Diabetes, 49, 2000, 6, S. 926-935 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Diabetes Association
|
| Schlagwörter: |
| author_facet |
Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C |
|---|---|
| author |
Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C |
| spellingShingle |
Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C Diabetes Effects of glucosamine infusion on insulin secretion and insulin action in humans. Endocrinology, Diabetes and Metabolism Internal Medicine |
| author_sort |
monauni, t |
| spelling |
Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C 0012-1797 1939-327X American Diabetes Association Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.2337/diabetes.49.6.926 <jats:p>Glucose toxicity (i.e., glucose-induced reduction in insulin secretion and action) may be mediated by an increased flux through the hexosamine-phosphate pathway. Glucosamine (GlcN) is widely used to accelerate the hexosamine pathway flux, independently of glucose. We tested the hypothesis that GlcN can affect insulin secretion and/or action in humans. In 10 healthy subjects, we sequentially performed an intravenous glucose (plus [2-3H]glucose) tolerance test (IVGTT) and a euglycemic insulin clamp during either a saline infusion or a low (1.6 micromol x min(-1) x kg(-1)) or high (5 micromol x min(-1) x kg(-1) [n = 5]) GlcN infusion. Beta-cell secretion, insulin (SI*-IVGTT), and glucose (SG*) action on glucose utilization during the IVGTT were measured according to minimal models of insulin secretion and action. Infusion of GlcN did not affect readily releasable insulin levels, glucose-stimulated insulin secretion (GSIS), or the time constant of secretion, but it increased both the glucose threshold of GSIS (delta approximately 0.5-0.8 mmol/l, P &lt; 0.03-0.01) and plasma fasting glucose levels (delta approximately 0.3-0.5 mmol/l, P &lt; 0.05-0.02). GlcN did not change glucose utilization or intracellular metabolism (glucose oxidation and glucose storage were measured by indirect calorimetry) during the clamp. However, high levels of GlcN caused a decrease in SI*-IVGTT (delta approximately 30%, P &lt; 0.02) and in SG* (delta approximately 40%, P &lt; 0.05). Thus, in humans, acute GlcN infusion recapitulates some metabolic features of human diabetes. It remains to be determined whether acceleration of the hexosamine pathway can cause insulin resistance at euglycemia in humans.</jats:p> Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes |
| doi_str_mv |
10.2337/diabetes.49.6.926 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjMzNy9kaWFiZXRlcy40OS42LjkyNg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjMzNy9kaWFiZXRlcy40OS42LjkyNg |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Diabetes Association, 2000 |
| imprint_str_mv |
American Diabetes Association, 2000 |
| issn |
0012-1797 1939-327X |
| issn_str_mv |
0012-1797 1939-327X |
| language |
English |
| mega_collection |
American Diabetes Association (CrossRef) |
| match_str |
monauni2000effectsofglucosamineinfusiononinsulinsecretionandinsulinactioninhumans |
| publishDateSort |
2000 |
| publisher |
American Diabetes Association |
| recordtype |
ai |
| record_format |
ai |
| series |
Diabetes |
| source_id |
49 |
| title |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_unstemmed |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_full |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_fullStr |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_full_unstemmed |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_short |
Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_sort |
effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| topic |
Endocrinology, Diabetes and Metabolism Internal Medicine |
| url |
http://dx.doi.org/10.2337/diabetes.49.6.926 |
| publishDate |
2000 |
| physical |
926-935 |
| description |
<jats:p>Glucose toxicity (i.e., glucose-induced reduction in insulin secretion and action) may be mediated by an increased flux through the hexosamine-phosphate pathway. Glucosamine (GlcN) is widely used to accelerate the hexosamine pathway flux, independently of glucose. We tested the hypothesis that GlcN can affect insulin secretion and/or action in humans. In 10 healthy subjects, we sequentially performed an intravenous glucose (plus [2-3H]glucose) tolerance test (IVGTT) and a euglycemic insulin clamp during either a saline infusion or a low (1.6 micromol x min(-1) x kg(-1)) or high (5 micromol x min(-1) x kg(-1) [n = 5]) GlcN infusion. Beta-cell secretion, insulin (SI*-IVGTT), and glucose (SG*) action on glucose utilization during the IVGTT were measured according to minimal models of insulin secretion and action. Infusion of GlcN did not affect readily releasable insulin levels, glucose-stimulated insulin secretion (GSIS), or the time constant of secretion, but it increased both the glucose threshold of GSIS (delta approximately 0.5-0.8 mmol/l, P &lt; 0.03-0.01) and plasma fasting glucose levels (delta approximately 0.3-0.5 mmol/l, P &lt; 0.05-0.02). GlcN did not change glucose utilization or intracellular metabolism (glucose oxidation and glucose storage were measured by indirect calorimetry) during the clamp. However, high levels of GlcN caused a decrease in SI*-IVGTT (delta approximately 30%, P &lt; 0.02) and in SG* (delta approximately 40%, P &lt; 0.05). Thus, in humans, acute GlcN infusion recapitulates some metabolic features of human diabetes. It remains to be determined whether acceleration of the hexosamine pathway can cause insulin resistance at euglycemia in humans.</jats:p> |
| container_issue |
6 |
| container_start_page |
926 |
| container_title |
Diabetes |
| container_volume |
49 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344673827684355 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:11:19.569Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Effects+of+glucosamine+infusion+on+insulin+secretion+and+insulin+action+in+humans.&rft.date=2000-06-01&genre=article&issn=1939-327X&volume=49&issue=6&spage=926&epage=935&pages=926-935&jtitle=Diabetes&atitle=Effects+of+glucosamine+infusion+on+insulin+secretion+and+insulin+action+in+humans.&aulast=Bonadonna&aufirst=R+C&rft_id=info%3Adoi%2F10.2337%2Fdiabetes.49.6.926&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344673827684355 |
| author | Monauni, T, Zenti, M G, Cretti, A, Daniels, M C, Targher, G, Caruso, B, Caputo, M, McClain, D, Del Prato, S, Giaccari, A, Muggeo, M, Bonora, E, Bonadonna, R C |
| author_facet | Monauni, T, Zenti, M G, Cretti, A, Daniels, M C, Targher, G, Caruso, B, Caputo, M, McClain, D, Del Prato, S, Giaccari, A, Muggeo, M, Bonora, E, Bonadonna, R C, Monauni, T, Zenti, M G, Cretti, A, Daniels, M C, Targher, G, Caruso, B, Caputo, M, McClain, D, Del Prato, S, Giaccari, A, Muggeo, M, Bonora, E, Bonadonna, R C |
| author_sort | monauni, t |
| container_issue | 6 |
| container_start_page | 926 |
| container_title | Diabetes |
| container_volume | 49 |
| description | <jats:p>Glucose toxicity (i.e., glucose-induced reduction in insulin secretion and action) may be mediated by an increased flux through the hexosamine-phosphate pathway. Glucosamine (GlcN) is widely used to accelerate the hexosamine pathway flux, independently of glucose. We tested the hypothesis that GlcN can affect insulin secretion and/or action in humans. In 10 healthy subjects, we sequentially performed an intravenous glucose (plus [2-3H]glucose) tolerance test (IVGTT) and a euglycemic insulin clamp during either a saline infusion or a low (1.6 micromol x min(-1) x kg(-1)) or high (5 micromol x min(-1) x kg(-1) [n = 5]) GlcN infusion. Beta-cell secretion, insulin (SI*-IVGTT), and glucose (SG*) action on glucose utilization during the IVGTT were measured according to minimal models of insulin secretion and action. Infusion of GlcN did not affect readily releasable insulin levels, glucose-stimulated insulin secretion (GSIS), or the time constant of secretion, but it increased both the glucose threshold of GSIS (delta approximately 0.5-0.8 mmol/l, P &lt; 0.03-0.01) and plasma fasting glucose levels (delta approximately 0.3-0.5 mmol/l, P &lt; 0.05-0.02). GlcN did not change glucose utilization or intracellular metabolism (glucose oxidation and glucose storage were measured by indirect calorimetry) during the clamp. However, high levels of GlcN caused a decrease in SI*-IVGTT (delta approximately 30%, P &lt; 0.02) and in SG* (delta approximately 40%, P &lt; 0.05). Thus, in humans, acute GlcN infusion recapitulates some metabolic features of human diabetes. It remains to be determined whether acceleration of the hexosamine pathway can cause insulin resistance at euglycemia in humans.</jats:p> |
| doi_str_mv | 10.2337/diabetes.49.6.926 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjMzNy9kaWFiZXRlcy40OS42LjkyNg |
| imprint | American Diabetes Association, 2000 |
| imprint_str_mv | American Diabetes Association, 2000 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0012-1797, 1939-327X |
| issn_str_mv | 0012-1797, 1939-327X |
| language | English |
| last_indexed | 2024-03-01T17:11:19.569Z |
| match_str | monauni2000effectsofglucosamineinfusiononinsulinsecretionandinsulinactioninhumans |
| mega_collection | American Diabetes Association (CrossRef) |
| physical | 926-935 |
| publishDate | 2000 |
| publishDateSort | 2000 |
| publisher | American Diabetes Association |
| record_format | ai |
| recordtype | ai |
| series | Diabetes |
| source_id | 49 |
| spelling | Monauni, T Zenti, M G Cretti, A Daniels, M C Targher, G Caruso, B Caputo, M McClain, D Del Prato, S Giaccari, A Muggeo, M Bonora, E Bonadonna, R C 0012-1797 1939-327X American Diabetes Association Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.2337/diabetes.49.6.926 <jats:p>Glucose toxicity (i.e., glucose-induced reduction in insulin secretion and action) may be mediated by an increased flux through the hexosamine-phosphate pathway. Glucosamine (GlcN) is widely used to accelerate the hexosamine pathway flux, independently of glucose. We tested the hypothesis that GlcN can affect insulin secretion and/or action in humans. In 10 healthy subjects, we sequentially performed an intravenous glucose (plus [2-3H]glucose) tolerance test (IVGTT) and a euglycemic insulin clamp during either a saline infusion or a low (1.6 micromol x min(-1) x kg(-1)) or high (5 micromol x min(-1) x kg(-1) [n = 5]) GlcN infusion. Beta-cell secretion, insulin (SI*-IVGTT), and glucose (SG*) action on glucose utilization during the IVGTT were measured according to minimal models of insulin secretion and action. Infusion of GlcN did not affect readily releasable insulin levels, glucose-stimulated insulin secretion (GSIS), or the time constant of secretion, but it increased both the glucose threshold of GSIS (delta approximately 0.5-0.8 mmol/l, P &lt; 0.03-0.01) and plasma fasting glucose levels (delta approximately 0.3-0.5 mmol/l, P &lt; 0.05-0.02). GlcN did not change glucose utilization or intracellular metabolism (glucose oxidation and glucose storage were measured by indirect calorimetry) during the clamp. However, high levels of GlcN caused a decrease in SI*-IVGTT (delta approximately 30%, P &lt; 0.02) and in SG* (delta approximately 40%, P &lt; 0.05). Thus, in humans, acute GlcN infusion recapitulates some metabolic features of human diabetes. It remains to be determined whether acceleration of the hexosamine pathway can cause insulin resistance at euglycemia in humans.</jats:p> Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes |
| spellingShingle | Monauni, T, Zenti, M G, Cretti, A, Daniels, M C, Targher, G, Caruso, B, Caputo, M, McClain, D, Del Prato, S, Giaccari, A, Muggeo, M, Bonora, E, Bonadonna, R C, Diabetes, Effects of glucosamine infusion on insulin secretion and insulin action in humans., Endocrinology, Diabetes and Metabolism, Internal Medicine |
| title | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_full | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_fullStr | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_full_unstemmed | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_short | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_sort | effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| title_unstemmed | Effects of glucosamine infusion on insulin secretion and insulin action in humans. |
| topic | Endocrinology, Diabetes and Metabolism, Internal Medicine |
| url | http://dx.doi.org/10.2337/diabetes.49.6.926 |